Assuit university ( South Egypt Cancer Institute )
Asyut, Egypt
NCT Number: NCT07113418
The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
Trial opening soon.
Get NotifiedFemale
Observational
Asyut, Egypt
Breast cancer is the most common malignant tumor in women, accounting for about 30 %, and its mortality rate is15 % of the incidence rate.
Studies in recent years have shown that the incidence of breast cancer is increasing year by year, which seriously affects Women's quality of life.
Several hormonal. metabolic and inflammatory mechanisms are known to play a role in the development and progression of breast cancer.
Fibroblast growth factor 21 (FGF21) is a protein produced mainly in the liver and regulated by diseases.The elucidation of the endocrine FGF21 signaling pathways in the control of metabolic disease, peroxisome proliferator-activated receptor-α (PPAR-α) which functions in lipid metabolism. However, more data support a versatile role for this molecule acting as a physiologic alert system in several energy homeostasis and their complications has raised great interest and hope in the last year.
Cancer-associated fibroblasts are activated fibroblasts that serve as a key component of the tumor receptors. FGFR1 is often overexpressed in breast and lung cancer, Promoter hypermethylation correlates microenvironment; FGF-19, FGF-21 and FGF-23 are endocrine FGFs that bind to Klotho and FGF with poorer survival of patients.
Clearly, further studies are needed to elucidate the mechanisms behind the increased serum FGF21 levels a high FGF21 secretion by the liver and also by the tumor cells or the stress caused by microenvironment condition that induces an increased FGF21 secretion by mainly the hepatocytes or/and adipocytes in less in cancer patients. It is believed that the elevated FGF21 levels observed in these patients could be due to metabolic disorders. Alternatively, the initiation of the tumor itself could be considered as a stressful degree. A study shows that Circulating FGF-21 level is associated with increased risk of early and late stages of (11)Another study shows that FGF21 is useful as a diagnostic as well as prognostic factor in patients with colorectal carcinogenesis ,supporting a role of inflammation and metabolism atall stages of colorectal carcinogenesis, and suggesting potential use of this biomarker for risk stratification in CRCscreening. endometrioid endometrial carcinoma.
The role of FGF21 in breast cancer and its level is not adequatelyincluded however a study byRanuncolo etal., revealed increased serum level as well astissue expression level of FGF21 in breast cancer.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Female patients admitted at south Egypt cancer institute who diagnosed as breast cancer basedon full clinical, radiological and pathological assays.
-
Exclusion criteria
Patients diagnosed with other concomitant cancers.
-
Enzyme-Linked Immunosorbent Assay. It's a lab technique used to detect and measure specific proteins like antibodies or antigens in a biological sample using enzyme-linked antibodies. When a substrate is added, the enzyme causes a color change, which makes it easy to measure the result accurately.
Time frame: At enrollment
Contact information is provided by the study sponsor or research team.
Asmaa Asmaa Mohamed Zahran, Professor
CONTACT
Asmaa Asmaa Mostafa Ali, Resident doctor
CONTACT
Assiut University
Other
Role of Fibroblast Growth Factor 21(FGF21) in Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07619534
Breast Cancer, Breast Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT07735897
Breast Cancer, Breast Diseases
Seoul, Sondpagu, South Korea
View Trial DetailsNCT07739563
Behavior, Breast Cancer
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07737132
Breast Cancer, Breast Diseases
View Trial Details